Find 2 more new buyers similar to 
Management Team - Mesoblast Ltd
Fred Grossman , DO, FAPA Chief Medical Officer Dr Grossman has over 20 years of industry experience, and has held key leadership positions at majo...
Jan 11, 2022
Coya Therapeutics
2023-present (2 years)
Headquartered in Houston, TX, Coya Therapeutics is a clinical-stage biotechnology company developing first-in-class and best-in-class approaches utilizing adoptive regulatory T cells (Tregs) to target disease. The company's CTreg (Cryopreservation for Tregs) system is patent pending and the first in the industry to overcome prior limitations of Treg cell therapies, allowing for serial infusions from a single manufacturing run. Coya's proprietary TAI (Tregs Against Inflammation) involves the conversion of millions of dysfunctional Tregs into billions of "Super Tregs" with superior immunosuppressive functionality. Our patent pending is EXO (immunosuppressive cell Exosome) platform is a Treg-derived exosome asset focused on the advancement of disease modifying approaches to address the significant unmet medical needs of patients with ALS, Frontotemporal Dementia, Parkinson's, Alzheimer's, and autoimmune diseases.
